anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a hair-bleaching agent and an oxidation hair dye each of which hardly gives an irritating smell, scarcely irritates scalps, and hardly gives a load to hair.  &lt;P&gt;SOLUTION: The hair-bleaching agent comprising the first agent containing an alkali agent and the second agent containing an oxidizing agent as a main ingredient is characterized in that the first agent contains 0.2 to 6 wt. % of ammonia and 0.1 to 20 wt. % of monoethanolamine hydrochloride and has a pH value of 8 to 12. The oxidation hair dye comprising the first agent containing at least one selected from oxidation dyes and direct dyes and an alkali agent and the second agent containing an oxidizing agent as a main ingredient is characterized in that the first agent contains 0.2 to 6 wt. % of ammonia and 0.1 to 20 wt. % of monoethanolamine hydrochloride and has a pH value of 8 to 12.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The invention relates to compositions which can be used as antiseptic for the skin and disinfectant for the hands. The compositions contain an alkyl alcohol component, at least one glycerol monoalkyl ether and water. They are particularly well tolerated by skin and sustainedly counteract degreasing and thus care for the skin. At the same time, they are fast-acting antiseptics for the skin and disinfectants for the hands which are not impaired, either in their effects or in their use properties, by skin-care components. In addition, they confer a pleasant feel to the skin. &lt;IMAGE&gt;
The present invention relates to the field of biological medicines. Disclosed are a fusion protein, and a manufacturing method therefor and an application thereof. The fusion protein comprises a polypeptide specifically binding to a KRas protein, a tumor cell-specific cell penetrating peptide and a lysosome recognition peptide. In the present invention, for the first time, a fusion protein having tumor targeting and penetrability and protein specificity degradation is constructed for an &#34;undruggable&#34; protein design, and a new idea is provided for development of anticancer targeted drugs. The fusion protein can simultaneously induce degradation of wild type and mutant KRas proteins, which is different from the case in the prior art that one molecule can only target one target protein. Moreover, the fusion protein can improve the sensitivity of a KRas mutant tumor on a tumor targeting drug by inducing KRas degradation, thereby expanding the application range of existing anticancer targeting drugs, and the invention has great significance in clinical tumor treatment.
The present invention provides relates to an edible composition for anti-diabetic benefit. Diabetes is one of the major and commonly occurring health problems in today&#39;s world. Pharmaceuticals companies are very active in this field to develop new medicines for preventing and controlling diabetes. There are several medicines available in the market for the treatment of type 2 diabetes. There are also prior arts which describes composition for the prevention of glucose intolerance and/or diabetes. We have found that though prior that discloses compositions for prevention of glucose intolerance and/or diabetes, it is not that effective for preventing diabetes. The present inventors while working extensively for providing an edible composition for preventing diabetes have surprisingly found that a particular combination of Inula racemosa and theobromine is effective for controlling and/or preventive diabetes thereby satisfying one or more of the aforesaid objects.
The invention is a kind of medicine which can cure hydrophobia in paroxysm. In order to solve the problem that the hydrophobia in paroxysm can&#39;t be cured, the invention provides a kind of Chinese traditional medicine to cure hydrophobia in paroxysm. The materials are: cantharis, cyperaceous, talcum and sticky rice. The merit of the invention is: the effect is outstanding, no recrudescence. The method is simple, low cost. It can be produced into powder, capsule, and pill.
PURPOSE:To efficiently prepare an extract containing phthalides in a high concentration from a natural plant by employing carbon dioxide in a liquid state or in a supercritical state as a solvent. CONSTITUTION:A plant (e.g. celery) or a galenical (e.g. Angelica acutiloba or Cnidium officinale) containing phthalides is treated with carbon dioxide in a liquid state or in a supercritical state at 10-80 deg.C, preferably 10-50 deg.C, under a pressure of 70-500-kg/cm&lt;2&gt;, preferably 200-400kg/cm&lt;2&gt;, to prepare an extract containing the phthalides. The addition of an alcohol and/or water to the carbon dioxide permits to improve the yield of the phthalides. After the plant is extracted, the carbon dioxide is gasified under vacuum to perfectly separate from the extract, thereby permitting to unnecessitate an extract-concentrating process.
The present invention involves labeling monoclonal antibodies with intermediate half-life radionuclides which decay to much shorter half-life daughters with desirable high energy beta emissions. Since the daughter will be in equilibrium with the parent, it can exert an in-situ tumoricidal effect over a prolonged period in a localized fashion, essentially as an &#34;in-vivo generator&#34;. This approach circumvents the inverse relationship between half-life and beta decay energy. Compartmental modeling was used to determine the relative distribution of dose from both parent and daughter nuclei in target and non-target tissues. Actual antibody biodistribution data have been used to fit realistic rate constants for a model containing tumor, blood, and non-tumor compartments. These rate constants were then used in a variety of simulations for two generator systems, Ba-128/Cs-128 (t 1/2  =2.4d/3.6m) and Pd-112/Ag-112 (t 1/2  =0.9d/192m). The results show that higher tumor/background dose ratios may be achievable by virtue of the rapid excretion of a chemically different daughter during the uptake and clearance phases. This modeling also quantitatively demonstrates the favorable impact on activity distribution of a faster monoclonal antibody tumor uptake, especially when the antibody is labeled with a radionuclide with a comparable half-life.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a stable foul breath inhibitor having a sustainable prevention effect on foul breath and to provide a method for preventing foul breath using the same.  &lt;P&gt;SOLUTION: The oily composition for lip comprises a green tea oil extract extracted from green tea by using an oil and a liquid oil component. The oily composition for lip has an excellent stability, provides a more excellent prevention effect on foul breath by application to lips and maintains the effect long. The oily composition for lip further comprises one or more kinds of compounds selected from a solid oil component, a semisolid oil component, an oil gelling agent and fine particle silica and improves storage stability with time of the oily composition for lip by including one or more kinds of the compounds. The improved effect is effective in the oily composition for lip especially having a low hardness. The shape and usability of the oily composition for lip are widened, for example, the stick-like oily composition for lip is prepared. The addition of the fine particle silica exhibits an effect of obtaining a sense of use of heavy feel.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a food composition, a medicinal composition or a cosmetic composition, giving excellent bleaching and cosmetic effects, originated from natural edible plants and safely ingestible for a long time without adverse effects.  &lt;P&gt;SOLUTION: This bleaching and cosmetic composition contains a solvent extract of fruit, pericarp and segment membrane of Satsuma orange. The solvent extraction is carried out by using one or more solvents selected from n-hexane, ether, acetone, ethyl acetate, methanol, ethanol, isopropanol, butanol, 1, 3-butylene glycol, ethylene glycol, glycerol and water. The composition contains the extract containing β-cryptoxanthin and hesperidin. A food and drink, a food additive, a medicine, a cosmetic and a quasi drug containing the extracts are provided.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE: To provide a dispersion for vesicles which is prepd. by mixing specific salicylic acid deriv. into lipid forming the vesicle films of amphiphilic lipid, has high physicochemical stability, adequate permeability and high capsulation level and has antiacne activity. CONSTITUTION: This compsn. for the acne application by topical application contains a dispersion, in a water phase D, of the vesicles of amphiphilic lipid which consists of the lipid phase films formed by capsulation of an aq. phase E and of which the lipid phase contains the charged lipid. The salicylic acid deriv. of the formula (R is straight chain or branched chain 11 to 17C alkyl; R&lt;1&gt; &#39; to R&lt;3&gt; &#39; are 1 to 18C alkyl or hydroxyalkyl, one of which can be benzyl) acting as the charged lipid and antiacne component; for example, 5-N- dodecanoilsalicylic acid N, N-dimethyl-N-(2-hydroxyethyl)ammonium are incorporated at 3 to 10 wt.% into the lipid phase. The compsn. in which the amphiphilic lipid exists at 0.5 to 25 wt.% of the total weight thereof and the average of the vesicles is 100 to 500 nm is preferable.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an IL-6 signal transmission-antagonizing peptide.  &lt;P&gt;SOLUTION: The peptide which inhibits signal transmission by binding a ligand to a receptor for controlling vital reactions and recognizes the three-dimensional structure of the molecule has been obtained from a random peptide library having a cysteine residue at the N-terminal side and totally comprising 35 residues by an in vitro virus method which is an evolutionary engineering means. Tests for obtaining a functional peptide high in specificity and affinity from enormous libraries have been performed to find a homologous peptide. Especially, it has been found that the functions of the peptide by a method of cysteine residues forming two or more S-S bonds and S-S cross-links thereof are largely changed. The peptide is an IL-6 signal transmission-antagonizing peptide having a function for binding to the receptor of IL-6 to inhibit the bonding of IL-6 to IL-6 receptor.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
1. Use of pregelatinized starch in a hydrophilic controlled release formulation comprising one or more active ingredients and one or more viscous hydrophilic polymers to counter the impairing effect of ionic strength of the release medium on the controlled release of active ingredient (s) from said formulation. 2. Use of pregelatinized starch in a hydrophilic controlled release formulation comprising one or more active ingredients and one or more viscous hydrophilic polymers to maintain a controlled release of active ingredient (s) from said formulation in release media with changing ionic strength. 3. Use of pregelatinized starch according to claim 1 or 2 wherein the ionic strength of the release medium ranges up to 0.4. 4. Use of pregelatinized starch according to claim 1 or 2 wherein the ionic strength of the release medium is that encountered along the entire gastro-intestinal tract both in fasted as well as in fed conditions. 5. Use of pregelatinized starch according to claim 1 or 2 wherein the ionic strength of the release medium ranges from about 0.01 to about 0.2. 6. Use of pregelatinized starch in a hydrophilic controlled release formulation comprising one or more active ingredients and one or more viscous hydrophilic polymers to prevent dose-dumping from said formulation along the gastro-intestinal tract both in fasted as well as in fed conditions. 7. Use of pregelatinized starch according to claims 1, 2 or 6 wherein the hydrophilic controlled release formulation further comprises pharmaceutically acceptable formulating agents. 8. A hydrophilic controlled release formulation according to any one of claims 1-7 comprising pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers and optionally pharmaceutically acceptable formulating agents characterized in that the pregelatinized starch enables the formulation to maintain a controlled release of the incorporated active ingredient (s) in release media with changing ionic strength. 9. A formulation according to claim 8 having the following composition: Active ingredient (s) 0.01-50% (w/w), Viscous hydrophilic polymer (s) 0.01-80% (w/w), Pregelatinized starch 0.01- &lt; 80% (w/w), Pharmaceutically acceptable formulating agents ad 100% (w/w). 10. A formulation according to claim 9 wherein the viscous hydrophilic polymer comprises hydroxypropyl cellulose. 11. A formulation according to claims 8, 9 or 10 further comprising a water soluble polymer as dissolution-rate enhancer. 12. A formulation according to claim 11 wherein the water soluble polymer is hydroxypropyl beta-cyclodextrin. 15. A formulation according to any one of claims 8, 9, 10, 11 or 12 wherein comprising a dosage form shaped as an optionally coated tablet.
242,323. Clark, G. M., (Knoll &amp; Co., Chemische Fabriks). July 4, 1924. Medicines for internal use; capsules; special shapes and forms; coatings for medicines.- Medicines such as natural or synthetic camphor, santal oil, ethereal oils, alkaloids, and brominated or iodized fats, which will not dissolve in the mixtures of gelatine, glycerine, and water commonly used in making pastilles, are dissolved in an anhydrous mixture of gelatine and glycerine. The pastilles are intended to be swallowed whole, and may be rendered tasteless by means of a layer of non-medicated gelatine, and may be treated with formaldehyde to prevent digestion until the reach the intestine. The non-medicated coating may be applied by coating both sides of a slab of the medicated composition with a solution of gelatine, drying, and stamping out tablets or pearls, or pastilles without a coating may be immersed in alcohol to dissolve the medicament out of the external layer and then washed and dried. Examples are given relating to mixtures of one part gelatine to three parts glycerine medicated respectively with camphor, synthetic camphor, chenopodium oil, camphor and papaverine and a salt of quinine.
PURPOSE:To provide a collagen metabolism-activating agent acting on human fibroblasts for enhancing their collagen-producing ability lowered by a pathogenic cause or a physiological cause such as aging. CONSTITUTION:The collagen metabolism-activating agent contains a sulfuric acid hydrolysate of silk fibers having a mol.wt. of &lt;=500. A hydrolysate produced by directly adding 40-60vol.% of sulfuric acid to scoured silk fibers and treating the scoured silk fibers at 60 deg.C for 1-48hr or a hydrolysate produced by preliminarily treating the silk fibers with calcium chloride, etc., and subsequently adding sulfuric acid to the solution of the produced solubilized fibroin. etc., can be used as the sulfuric acid hydrolysate of the silk fiber. This collagen metabolism-activating agent is employed in the forms of various preparations such as a solution, a solid agent and a semi-solid agent, and the addition amount of the collagen metabolism-activating agent is usually 0.1-10wt.%, preferably 1-5wt.%, based on a composition to be applied, in the case of the activating agent containing 0.5-4wt.% of the hydrolysate as the silk fibers.
PURPOSE:To obtain new antibiotic substance AB4015-B and AB4015-L having antibacterial activity and plant blight pathogen controlling activity and useful as an antibacterial agent, fungicide for agricultural and horticultural use, etc., by culturing a microorganism which belongs to the genus Phoma, capable of producing antibiotic substance AB4015-B in a medium and separating the substance from the cultured product. CONSTITUTION:A microorganism which belongs to the genus Phoma, capable of producing antibiotic substance AB4015-B [e.g. Phoma sp. AB4015 (FERM P-13206)] is inoculated to a medium and cultured at 25 deg.C under shaking for 5 days using a rotary shaker. The microbial cells are collected by filtering the culture liquid, extracted by adding methanol and filtered to obtain a cell extract liquid. The extract is mixed with water and chloroform and extracted by thoroughly shaking the mixture. The chloroform layer is collected and concentrated under reduced pressure and the concentrate is purified by chromatography to obtain the new antibiotic substance expressed by the formula I (R&lt;1&gt; is group of the formula II and R&lt;2&gt; is group of the formula III for AB4015-B; R&lt;1&gt; is group of the formula IV and R&lt;2&gt; is group of the formula V for AB4015-L).
1,205,618. Enolic ethers of adipic dialdehydes. UGINE KUHLMANN. 16 Feb., 1968 [9 March, 1967], No. 7791/68. Heading C2C. New enolic mono- and diethers of adipic dialdehydes of the general formulµ wherein R is the same or different and represents hydrogen, C 1-4  alkyl or optionally substituted phenyl and R&lt;SP&gt;1&lt;/SP&gt; represents C 1-4  alkyl optionally substituted by halogen, hydroxy or nitrile, are prepared by heating a mono- or diether of 1,5-hexadiene-3,4-diol of formulae or their mixtures, to high temperatures to realise a Cope transposition. The process may be performed in the liquid phase in an inert, thermally stable solvent such as an aliphatic or aromatic hydrocarbon or an ether such as diphenylether, at atmospheric pressure and at the boiling point of the mixture. 0À01-1% of a polymerization inhibitor may be included, e.g. hydroquinone, monomethyl ether of hydroquinone, t-butyl-catechol, p-phenylene diamine or a copper salt. The heating time for the process may be 1/3-5 hours. The process may also be performed in the gaseous phase by passing the vapours of the starting material diluted if desired in an inert gas such as nitrogen, argon or CO 2 , into a duct which may contain matter inert to the vapours. These novel compounds may be used to generate the corresponding adipic dialdehydes since they are easily hydrolysed in a slightly acidic medium and thus may be made as disinfectants for water, textiles as bactericides, as reticulating and insolubilizing agents for proteins or polyhydroxylated polymers, in textile stiffening, paper treatment, reticulation of polyvinylic alcohols or other hydroxylated polymers. Also they may be used as monomers to carry out polymerization or copolymerization reactions with other vinylic monomers and are raw materials for the preparation of many di- or polyfunctional compounds such as 1,6-hexanediols and 1,6- diaminohexanes.
A synthetic gene encoding a 71-amino acid analog of human insulin-like growth factor (hIGF-I) has been constructed and expressed in the yeast, Saccharomyces cerevisiae. The protein analog, IGF132, contains the first 17 amino acids of the B chain of human insulin in place of the first 16 amino acids of hIGF-I. The purified hybrid protein has high affinity for the type I IGF receptor (12 nM) yet has drastically reduced affinity for human serum carrier proteins (&gt;1000 nM). This analog is 5 to 10 times more active than normal hIGF-I in stimulating DNA synthesis in 3T3 cells and is a more active growth factor in vivo due to its reduced affinity for serum carrier proteins. Other proteins with similar properties have also been constructed. The protein analogs thus have a variety of utilities such as in promoting lactation in animals; promoting growth and feed efficiency in animals; improving carcass quality by increasing lean and decreasing fat; promoting wound healing in animals, including humans; promoting glucose utilization in skeletal muscle, and stimulating erythropoiesis, the production of red blood cells.
The present invention provides an oil controlling composition and an oil controlling cream containing the same. The oil controlling composition contains: 1-5 parts by weight of silicon dioxide; 2-10 parts by weight of hydrated silicon dioxide; and 10-15 parts by weight of emulsifier. The weight ratio of silicon dioxide to hydrated silicon dioxide is 1:2. The oil controlling cream contains: 63-77 parts by weight of water; 1-5 parts by weight of silicon dioxide; 2-10 parts by weight of hydrated silicon dioxide; 10-15 parts by weight of emulsifier; 7-9 parts by weight of polyglycerol and/or polyglycerol derivatives; and 0.1-0.3 parts by weight of preservative. The weight ratio of silicon dioxide to hydrated silicon dioxide is 1:2. By using the aforementioned oil controlling composition and oil controlling cream containing the same, the problems that the skin feels thick and easily get flakey when conventional cosmetic products are applied on user&#39;s face can be solved.
The invention relates to the technical field of biological medicines, in particular to a chimeric body for promoting tau protein dephosphorylation and application thereof. The chimera comprises a tau protein binding sequence, a linking sequence, a phosphatase recruiting sequence, and a transmembrane peptide sequence, the tau protein binding sequence and the phosphatase recruiting sequence being linked by the linking sequence; the amino acid sequence of tau protein binding sequence is shown in SEQ ID No. 1, and the amino acid sequence of phosphatase recruitment sequence is shown in SEQ ID No. 2. The chimera can be used for treating primary neurons of rats or transgenic mice with Alzheimer&#39;s disease, and can effectively reduce the levels of phosphorylated Tau protein and total Tau protein at Ser199, thr205, ser396, ser404, tau5 and other epitopes. Can remarkably improve the density and morphology of subcellular organelles and dendritic spines of mice with Alzheimer&#39;s disease and improve the learning and memory functions of the mice.
Methods and devices are provided for the extracorporeal ablation of target cells circulating in blood of an organism. Exogenous material introduced into the blood preferentially associates with target cells (e.g. cancer cells, bacteria, viruses) in the blood. An extracorporeal continuous flow pathway accesses the patient&#39;s blood to apply an external energy source to the blood at an ex vivo ablation device in a portion of the extracorporeal continuous flow pathway. The exogenous material interact with the applied energy so as to result in the damage or death of the target cells. The blood is then returned to the body in a continuous-flow pattern. By applying the energy while the blood is in the ex vivo ablation device, shielding of the target cells by the body is reduced and detrimental effects on the organs and tissues of the body are avoided or mitigated.
INHIBITORS OF BRUTON&#39;S TYROSINE KINASE Abstract Disclosed herein are compounds that form covalent bonds with Bruton&#39;s tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (64408731 ):KZA